If you or a loved one have been diagnosed with anal cancer, there are a range of options for treatment as well as new advancements emerging. The different treatment options also depend on the stage of anal cancer the patient is at, which we have broken down below.
Anal cancer treatment can include surgery, chemotherapy, and radiation as well as emerging therapies. There are treatments for squamous and non-squamous forms of anal cancer.
The treatment descriptions here are for general information and are based on general guidelines. However, the information on this site does not reflect medical advice. Talk to your medical provider about the best treatment options for you.
Treatment options for anal cancer depend on stage and type. The US National Comprehensive Cancer Network (NCCN) produces an in-depth anal cancer treatment guidelines document that is updated yearly. The document has a detailed and technical overview of treatment pathways and regimens.
These treatment regimens are primarily for squamous cell carcinoma, which accounts for more than 90% of all anal cancers. These are tumors that are caused by abnormal growth of squamous cells that line most of the anal canal and anal margin (where the anal canal meets the outside skin).
The remaining anal cancers are:
- Basal cell carcinomas of the perianal region: these are considered a subset of squamous cell carcinoma and are extremely rare – they comprise less than 1% of all abnormal growths of the anal region.
- Adenocarcinomas (around 5-19% of all anal cancers).
- Malignant melanomas (2-4% of all anal cancers).
Estimates of the prevalence of each of these anal cancers vary based on different studies. Find out more about the different types of anal cancer and the symptoms.
The Nigro Protocol
The standard protocols for treating anal cancer are listed in the NCCN guidelines and on the NHS website (UK).
For stages I – III, the standard protocol is radiation and chemotherapy, used in conjunction with one another (often called 'chemoradiation'). The combination of chemotherapy and radiation has been found to be more effective than surgery in treating these stages of anal cancer.
The chemotherapy and radiation protocols that have been used for decades are known collectively as the Nigro Protocol. The Nigro Protocol typically includes several weeks of radiation with two different types of chemotherapy given at the beginning and end of treatment.
Stage IV cancers are usually treated with systemic therapy, such as chemotherapy or a chemo-immunotherapy combination.
Treatment for anal cancer has remained overwhelmingly the same since the 1970s. The Nigro Protocol was established in 1974 and, unbelievably, there is no FDA-approved chemotherapy drug specific to anal cancer – a fact we are working to change. By working with scientists on novel research projects and investing in new tools for scientists to create better therapies, the Anal Cancer Foundation is reviving a once near-closed pipeline. Our goal is to increase the options for patients and accelerate new treatments that are less toxic and just as effective.
Read more below about the current protocol for surgery, chemotherapy, and radiation. For a helpful list of questions to have with you at your medical appointments, please see our list of Questions to Ask Your Doctor.
Chemotherapy
Chemotherapies are a class of drugs that kill cancer cells and prevent them from multiplying.
Anal cancers between stages I-III are often treated with the chemotherapy drugs mitomycin-C and 5-fluorouracil (5-FU) in addition to radiation.
For these individuals, chemotherapy is typically administered twice, once at the beginning of radiation and then again at 5 weeks of radiation. Before treatment, a temporary central venous catheter (“CVC”) or peripherally inserted central catheter (“PICC”) may be placed on an individual. These allow for chemo infusions from 96 to 120 hours at a time. 5-FU has also become available in pill form, which may be administered every day to patients who could benefit from taking it this way.
Common side effects of these drugs include, but are not limited to, decreased white blood cells, decreased red blood cells and/or platelets, nausea, vomiting, mouth sores, hair loss, neuropathy, and fatigue. Individuals taking these drugs should talk to their doctors about possible side effects and tell their doctors if they experience these or other side effects.
For stage IV anal cancer, current NCCN guidelines recommend carboplatin plus paclitaxel combined with retifanlimab-dlwr (a combination of platinum-based chemotherapy and immunotherapy). This recommendation is based on results from the phase III InterAACT-2 trial (POD1UM-303) which demonstrated that the addition of retifanlimab improved progression free survival and overall survival compared with carboplatin and paclitaxel alone. These findings led to the FDA approval of retifanlimab-dwlr for advanced anal cancer.
Earlier studies established the importance of the combination of carboplatin and paclitaxel. In 2020, the original InterAACT trial, a randomized international phase II study, took place to investigate the most effective chemotherapy regimen for recurrent or metastatic anal cancer. This 60-center international study compared the results of two treatment regimens for patients with locally recurrent or metastatic anal cancer. One arm consisted of cisplatin and 5-FU, and the other consisted of carboplatin and paclitaxel. Although overall response rates were the same between arms, reduced side effects and potentially longer survival rates led to the suggested adoption of carboplatin plus paclitaxel as a new standard of care.
There are also encouraging results from studies that have employed either a combination of paclitaxel, carboplatin, and 5-FU; or single-agent paclitaxel. Several other single-agent or combination treatments have been tested in clinical trials and case studies, with varying success, often based on strategies effective in lung cancer or head and neck cancers. However, these approaches are considered investigational and have not replaced the phase III validated chemotherapy and immunotherapy regimen used for stage IV disease. We believe a better standard of care for all stages of anal cancer needs to be established and support research to better understand and treat it.
For more information about preparing for chemotherapy, the side effects of chemotherapy, and how to manage them, please see our Chemotherapy page.
Cancer Research UK has put together a useful list of questions that you might want to ask your doctor specifically about chemotherapy for anal cancer.
Looking for someone to talk to about your anal cancer diagnosis? We are here to help.
Radiation
Radiation for anal cancer involves using an external beam of radiation that is directed toward the cancer location to shrink tumors and kill cancer cells. You are likely to have radiotherapy in combination with chemotherapy as your main form of treatment. For individuals with anal cancer stages I-III, radiation is typically 5 days a week for 5 to 6 weeks. Individuals with stage IV or recurrent cancer may receive radiation in locations where the cancer has spread.
You may not experience side effects at the beginning of treatment but should expect them as treatment progresses. You may feel the effects for a few weeks after completing treatment, too. This is because radiation has cumulative effects, meaning they build up over time. During radiation, it is important to take care of your skin and drink lots of liquids.
Side effects for radiation targeted at an anal tumor may include: skin irritation, gastrointestinal and anal discomfort, pain during bowel movements and while urinating, fatigue, diarrhea, and nausea. Women may experience side effects unique to their anatomy, including: vaginal pain, irregular vaginal discharge, and closure of the vagina through the accumulation of scar tissue called stenosis. Side effects unique to the male anatomy may include erectile dysfunction and impotence. Everyone may experience narrowing of the anus, making bowel movements difficult.
Individuals undergoing pelvic radiation for anal cancer may have gastrointestinal and sexual dysfunction that can last throughout their life. Due to the cancer’s location, individuals may experience a weakened pelvis and an inability to use their sphincter.
Please talk to your radiation oncologist about your specific treatment and side effects, as they vary from person to person. Ask your doctors about mitigating radiation side effects. Management aides may include moisturizers, lubricants, dilators, pelvic rehabilitation, and a referral to a sex therapist who is familiar with pelvic radiation side effects.
For more information about the side effects of radiation and how to manage them, please see our Radiation page.
Four weeks after my diagnosis, I was off to the radiation oncologist. I met the radiation team, received my tattoos (four very small dots used to line up the radiation machine) and they built a form to hold my legs during treatment. My legs were put together like a frog and the mold material was put around them. Within minutes they had a mold. Lying on my back on the table of the radiation machine, the ceiling had a wonderful backlit scene of clouds and blue sky. At least there was something to focus on during those 20 minutes lying still like a frog on that cold table! Talk about embarrassment! But that quickly subsides and it doesn’t matter who sees what anymore.
Sue B.
Stage IIIB
Surgery
Although anal cancer is primarily treated with chemotherapy and radiation protocols, there may be times when surgery is used.
Although uncommon, surgery can be used for early-stage anal cancer when the tumor is extremely small and localized. Your provider may refer to this type of cancer as “superficially invasive”. During surgery, the area in which cancer is present is excised (removed). This operation is called a local resection. If tests after the surgery show that there is no evidence of disease, the individual will be observed by their doctors. If the tests after surgery show that anal cancer is still present, the patient will undergo further treatment, which may include another excision or chemotherapy and radiation.
Ostomy and Abdominoperineal Resection
Another type of surgery is used for an ostomy. An ostomy is a surgically created opening in the abdominal wall used for the removal of bodily waste, i.e. stool or poop. The opening is called a stoma, and feces will pass through it into a special collection bag. You will need to learn to care for this area. A specialized stoma nurse will be able to help you with this.
There are different types of ostomies. For anal cancer, the most common ostomy is colostomy.
Some thrivers may need a temporary ostomy when they are going through chemoradiation treatment to help them avoid the pain of going to the bathroom, but this can be reversed after treatment.
There is a much more invasive surgery called an abdominoperineal resection (APR), which may be recommended later in treatment. This is especially in cases where chemoradiation has unsuccessfully treated the primary tumor, but cancer has not metastasized to other areas. In an APR the surgeon will remove the anus, rectum, part of the colon, and the lymph nodes.
Due to the nature of this surgery, you will need to have a permanent colostomy.
Please see our Ostomy Section in Side Effects of Surgery for more information about how to adjust to living with an ostomy, and be sure to speak with your care team about any questions or concerns you may have.
Cancer Research UK has put together a useful list of questions that you might want to ask your doctor about your anal cancer surgery.
Trea
tment for stage IIIB cancer isn’t any fun, but then I suppose no cancer treatment is a walk in the park. In January of 2010, I had a colostomy and then began simultaneous radiation and chemotherapy the day I got out of the hospital with my new ‘appliance’ (colostomy bag). It was my good fortune, or so my oncologist told me, that I was in perfect health except for the 7cm tumor hanging off…well…you know where. They treated the cancer very aggressively. I had radiation daily for 33 days along with 2 rounds of chemo where I had a bottle attached to my arm for a week during each round.
Karen, US
Stage IIIB
Treatments by Stage of Anal Cancer
Stages 0
Stage 0 anal cancer means that the abnormal cells are only at the very top layer of the anal lining. It is also called carcinoma in situ or AIN3 (AIN means anal intraepithelial neoplasia).
AIN is treated using topical (i.e., applied directly) therapies such as imiquimod, 5-flurouracil, and trichloroacetic acid. Ablative therapy can also be used—this is a minimally invasive treatment used to remove the top layer of skin, often with a laser.
If you have been diagnosed with AIN be sure to screen regularly to prevent abnormalities from developing into cancer. Learn more on our anal precancer + screening page.
Stages 1, 2 & 3
The standard of care to treat anal cancer stages I-III is combined chemoradiation therapy, otherwise known as the ‘Nigro Protocol’. See our sections above for more details.
Learn more about the side effects of chemotherapy and radiation.
Stage 4
For stage IV anal cancer, the main treatment is systemic therapy. This may involve chemotherapy alone or, in the United States, a chemo-immunotherapy combination. Read more about treatment for stage IV anal cancer
Treatment for Recurrent Anal Cancer
Cancer is called 'recurrent' when it returns after treatment. It may come back in the same area (local recurrence), in nearby lymph nodes (regional recurrence), or in distant organs such as the lungs, liver or bones.
If your cancer returns, your doctor will carry out tests to understand where it has come back and how far it has spread. This information helps guide treatment decisions, which depend on both the site of recurrence and the treatments you previously received.
For more information please see our section on Recurrent and Advanced Cancer.
Emerging Treatment Options
Immunotherapy
Immunotherapy is a type of treatment that helps the body's own immune system recognise and attack cancer cells. It works by targeting pathways that cancer cells use to hide from the immune system.
In the United States, a new immunotherapy called retifanlimab-dwlr is approved for some people with advanced anal cancer. It can be used together with chemotherapy for patients who have not received chemotherapy before, or on its own for those who cannot tolerate or whose cancer has progressed after platinum-based treatment.
Different types of immunotherapy are being studied for anal cancer, including cancer vaccines and checkpoint inhibitors. Research in this area is growing, but most immunotherapies remain available only through clinical trials.
Radiosensitizers
Radiosensitizing agents are drugs that increase the sensitivity of tumors to radiation by disrupting their DNA, making radiotherapy more effective. The hope is that lower doses of radiation and chemotherapy will be needed.
Clinical Trials
Clinical trials look at new ways to prevent, detect, or treat disease.
We list current anal cancer clinical trials from ClinicalTrials.gov on our Clinical Trials page. The registry is searchable and each listing provides info about the purpose of the trials, eligibility, the study location, and more. You can sort by cancer type, stage, and geography.
We recommend discussing everything you find with your medical team. They are often the ones who can hopefully connect you to the right enrollment process if you fit the profile.
Genomic Research
Genomic research is also a fast-growing and relatively new area of study in the cancer research world. Cancer genome research compares genes in tumors to genes in healthy, noncancerous tissues in order to understand important differences between the two.
The research goal is to provide insight into what drives cancer development. Ultimately, if we understand how a healthy cell’s DNA has changed to become cancerous, it may indicate areas of the genome that can be targeted by specific drugs. In the future this may mean that each individual has 'personalized' medicine where people are no longer treated by the anatomical site but by the genetic mutations in their tumor.
For more information on genomic research, please see our section on Recurrent and Advanced Cancer.
See our Research Roadmap for our vision to advance development of effective treatments for anal and all HPV-related cancers.
Treating Non-Squamous Forms of Anal Cancer
Other forms of anal cancer are adenocarcinoma, basal cell carcinoma, and malignant melanoma. Adenocarcinoma accounts for 5-19% of anal cancer, malignant melanoma for 2-4% and basal cell carcinoma for less than 1% of all abnormal anal growths.
ADENOCARCINOMA
This is a rare type of anal cancer that affects the glandular cells used in mucus production in the anal canal. On occasion, adenocarcinoma is treated with the Nigro Protocol, as described above, but for the most part it is treated in the same way as rectal cancer. Because of this, the treatment for rectal cancer is outlined below. As with squamous cell carcinomas, treatment varies by stage.
There is an ongoing discussion in the scientific community about whether these types of cancers should be classified as anal or rectal cancer. We consider all cancers that affect the anus as under the umbrella of anal cancer, and our resources are available to all.
Surgery is a common treatment for adenocarcinomas that are stage 0 or 1. Surgery can be minimally invasive in stage 0 cancers, which usually only require a local excision or transanal resection. In stage I cancers, the type of surgery required, and how invasive it is, usually depends on the location of the cancer. Additional therapy is not always needed after surgery but if the cancer turns out to be more advanced than previously thought, a combination of chemotherapy and radiation is usually advised.
In more advanced adenocarcinomas, such as stages II and III, chemotherapy and radiation therapy tends to be given prior to surgery. After surgery, more chemotherapy is given. This chemotherapy may be what is called the FOLFOX regimen (oxaliplatin, 5-FU and leucovorin), or it may be 5-FU and leucovorin, CapeOx (capecitabine plus oxaliplatin) or capecitabine alone. Please note that this is not an exhaustive list of treatment options and that you should discuss your individual treatment with your medical team. The regimen and dosage depend on your health status and needs.
Treatment options for stage IV are similar, but depend on where the cancer has spread. Your health status and ability to tolerate treatment are also taken into account when determining a course of action. Chemotherapy, radiation and surgery are usually prescribed in various combinations depending on your needs.
The American Cancer Society and the National Comprehensive Cancer Network (requires a free registration) both have in-depth information pages on the treatment of rectal cancer.
For more information about the side effects and how to manage them, please see our Radiation, Chemotherapy and Surgery pages.
BASAL CELL CARCINOMA
Basal cells make up part of the lowest layer of the epidermis, or skin. These cancers usually develop in areas exposed to sunlight and are, in fact the most common type of cancer in humans.
Anal basal cell carcinomas are rare, however. For the purposes of categorization for anal cancer, the NCCN considered basal cell carcinomas a subtype of squamous cell carcinomas.
Please see the National Comprehensive Cancer Network’s (requires a free registration) page for more in-depth information.
MALIGNANT MELANOMA
Melanoma develops from cells known as melanocytes, which produce melanin. This is the pigment responsible for the color of our skin. Melanocytes are found in our skin and hair, and in other internal organs, including the anus and rectum. Anal melanoma is quite rare, and is mostly found in older adults, aged 60-80. Anal melanoma follows the treatment protocols for melanoma.
As with other types of anal cancer, treatment will depend on the staging and position of the cancer, and your overall health and wellness. Surgery is usually the main option in these cases, as melanomas do not typically respond as well to chemotherapy and radiation as other types of anal cancer.
Early-stage melanomas are usually removed via local excision, while larger tumors or those that have grown into the deeper tissue are removed using abdominoperineal resection.
If the melanoma has spread to other organs, treatment usually involves chemotherapy and radiation, and may also include immunotherapy or targeted therapy drugs.
Please see the American Cancer Society and National Comprehensive Cancer Network’s treatment and patient guidelines pages (requires a free registration) for more in-depth information about melanoma treatment.
For more information about the side effects and how to manage them, please see our Radiation, Chemotherapy, and Surgery pages.
Anal Cancer and HIV
Immunocompromised people, such as those living with HIV are at greater risk of having high-grade AIN and/or anal cancer than other people.
Being consistent with HIV treatment and maintaining a high CD4 count can help protect against both of these. Being vigilant with screening for AIN too can help catch problematic cells early before they progress. Additionally, because people with HIV are, luckily, living longer due to effective treatment, these and other cancers have more time to develop.
The treatment regimen for people with is the same as for those without HIV, and treatment outcomes have generally been found to be similar.
It’s important to note that if you are diagnosed with anal cancer but haven’t been tested for HIV, your medical team may discuss testing with you. People who have anal cancer sometimes have undiagnosed HIV, and getting on effective treatment is definitely to the thriver’s benefit.
Treatment Side Effects
As we’ve discussed throughout, anal cancer treatments can cause side effects that may be quite uncomfortable. Side effects vary from person to person, and each individual thriver may not experience all of the side effects described, and in different intensities.
Learn more on our side effects of treatment page or jump to our Radiation, Chemotherapy and Surgery pages.
Palliative Care
Palliative care is specialized medical care that focuses on providing pain relief. Treatments vary widely and can involve medication, nutrition, mindfulness and relaxation practices, spiritual support, and more. Palliative care specialists work with you to provide that additional support that's meant to complement your direct cancer care. Make sure to speak with your medical team early in your treatment planning about what palliative care options are available to you. Receiving this type of care alongside traditional, more aggressive cancer therapies often has the impact of improving quality of life and treatment satisfaction.
Support During & After Treatment
Once treatment has concluded, individuals should expect to see their provider regularly for follow-up visits. These visits may include physical exams as well as tests to determine the presence or absence of anal cancer. At first, these visits typically occur every three months and gradually change to every six months after a two-year period. Generally, if a recurrence happens, it is in the first two years after treatment. If you are concerned about anything in between follow-up appointments, be sure to see your provider as soon as possible.
Anal cancer is considered uncommon, with an incidence rate in the US of 1.8 in 100,000 people. In 2020, around 8,600 people were predicted to be diagnosed with anal cancer in the US and 1,600 people in the UK. Due to its rarity and the stigma associated with it, it is extremely important for those with anal cancer to reach out to others in the community for information and support. Anal cancer does not need to be isolating. If you are interested in finding a peer to speak with, the Anal Cancer Foundation has a Peer to Peer Support Program specifically for individuals diagnosed with anal cancer and their caregivers.
Learn more about our support services.
The Anal Cancer Foundation also has what we call the RESET initiative, launched at our 2022 thriver summit. RESET provides anal cancer thrivers a roadmap to recovery after chemoradiation. Our goal is to arm every thriver (and their caregivers) with the knowledge and resources to move beyond their cancer.
RESET stands for:
- Relief from Pain
- Exercise the Pelvic Floor
- Support from Professionals and Peers
- Eating to Heal
- Therapy for Sexual Health
Peer-to-Peer Support
Anal cancer can often be an isolating experience, and even if you have a supportive circle of family and friends, unless they have been through anal cancer treatment themselves there is often a limit on their understanding. Our peer-to-peer support program aims to address this gap, matching anal cancer thrivers seeking support from trained peer mentors who have been through treatment. Mentors provide 1:1 connection from the framework of those who have shared within this incredibly difficult experience.
We also provide caregiver matching as well.
The cancer thrivers who participate in the program, whether offering or receiving mentorship, build deep friendships and express relief at having found a knowledgeable and empathetic community. After recovery, many support-seekers come back to serve as mentors in the program themselves.
Learn more about our Peer-to-Peer Support Program.
Anal Cancer Treatment FAQS
How does the choice of treatment for anal cancer vary depending on the stage and location of the tumor?
The choice of treatment for anal cancer can vary significantly based on the stage and location of the tumor. Here's a breakdown of how treatment approaches may differ:
Early-stage (Stage I) anal cancer:
- For small tumors localized to the anus, surgery may be the primary treatment option. This could involve procedures like local excision or transanal resection to remove the tumor.
- Alternatively, radiation therapy (often combined with chemotherapy) may be used as the primary treatment, particularly for tumors that are not amenable to surgery or for patients who are not suitable candidates for surgery.
Locally advanced (Stage II and III) anal cancer:
- For larger tumors or those that have spread to nearby lymph nodes, a combination of chemotherapy and radiation therapy (chemoradiation) is typically recommended as the primary treatment. This approach helps shrink the tumor and eradicate cancer cells in the surrounding area.
- In some cases, surgery may be performed after chemoradiation to remove any remaining tumor or to address persistent disease.
Metastatic (Stage IV) anal cancer:
- For anal cancer that has spread to distant organs or lymph nodes beyond the pelvis, systemic treatments such as chemotherapy or targeted therapy are typically employed.
- Surgery or radiation therapy may still be used in certain situations to alleviate symptoms or manage complications, but the primary goal of treatment at this stage is usually palliative rather than curative.
Location of the tumor:
- The precise location of the tumor within the anal canal can influence the choice of treatment. Tumors closer to the anal verge may be more amenable to surgical resection, while those located higher in the anal canal may be better treated with radiation therapy or chemoradiation.
- Additionally, tumors that involve the anal margin (the junction between the anus and the skin) may require a different surgical approach or may be more challenging to treat surgically due to cosmetic and functional considerations.
Overall, the stage and location of the tumor play crucial roles in determining the most appropriate treatment strategy for anal cancer, with the goal of achieving optimal outcomes while minimizing the risk of recurrence and preserving quality of life.
How do medical experts from different fields plaY a role in the treatment of anal cancer?
The multidisciplinary approach (this means experts from many different fields of medicine) plays a critical role in the treatment of anal cancer, primarily due to the complexity of the disease and the diverse expertise required to provide comprehensive care. Here's how different medical specialties collaborate in the management of anal cancer:
Medical Oncology: Medical oncologists specialize in the use of chemotherapy, targeted therapy, and other systemic treatments for cancer. They play a central role in coordinating chemotherapy regimens, both as part of definitive treatment (such as concurrent chemoradiation for locally advanced disease) and in the management of metastatic anal cancer.
Radiation Oncology: Radiation oncologists are responsible for planning and delivering radiation therapy to treat anal cancer. They work closely with medical oncologists to determine the optimal radiation dose and technique, taking into account factors such as tumor size, location, and stage. Radiation therapy is often a key component of treatment for anal cancer, either alone or in combination with chemotherapy.
Surgical Oncology: Surgical oncologists specialize in the surgical management of cancer. While surgery is not always the primary treatment for anal cancer, it may be necessary in certain cases, such as early-stage tumors or persistent disease after chemoradiation. Surgical oncologists may perform procedures such as local excision, abdominoperineal resection (APR), or inguinal lymph node dissection as part of the treatment plan.
Gastroenterology/Colorectal Surgery: Gastroenterologists and colorectal surgeons are involved in the diagnosis and management of anal cancer, particularly in evaluating patients with anal lesions and performing procedures such as biopsies and endoscopic evaluations. They may also be involved in the surgical management of anal cancer, particularly for tumors located in the anal canal or involving the anal margin.
Pathology: Pathologists analyze tissue samples (biopsies) obtained from anal lesions to establish a definitive diagnosis of anal cancer and provide important information about the tumor's characteristics, such as its histological type, grade, and molecular features. This information helps guide treatment decisions and prognostication.
Radiology: Radiologists play a crucial role in diagnosing anal cancer and assessing its extent through imaging studies such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Radiologists collaborate with other members of the multidisciplinary team to stage the disease accurately and monitor treatment response.
Supportive Care Providers: In addition to the core treatment specialties, supportive care providers such as nurses, oncology pharmacists, nutritionists, and social workers are essential members of the multidisciplinary team. They provide supportive care services, manage treatment-related side effects, address patients' psychosocial needs, and optimize quality of life throughout the treatment journey.
By bringing together specialists from various disciplines, the multidisciplinary approach ensures that patients with anal cancer receive individualized, evidence-based care that integrates the latest advances in treatment and supportive care. This collaborative model helps optimize treatment outcomes, minimize treatment-related complications, and improve overall patient satisfaction and well-being.
Are there specific factors or patient characteristics that can influence treatment options for anal cancer?
Yes, several factors and patient characteristics can influence treatment options for anal cancer. These include:
Stage of cancer: The stage of anal cancer, which indicates the extent of disease, is a crucial factor in determining the appropriate treatment approach. Treatment options may vary for early-stage (I and II) versus locally advanced (III) or metastatic (IV) disease.
Tumor size and location: The size and location of the tumor within the anal canal or surrounding tissues can impact treatment decisions. Tumors closer to the anal verge may be more amenable to surgical resection, while those located higher in the anal canal may be better treated with radiation therapy or chemoradiation.
Lymph node involvement: The presence or absence of lymph node involvement (regional lymph node metastasis) affects treatment planning and prognosis. Lymph node-positive disease may require more aggressive treatment, such as chemoradiation or lymph node dissection, compared to lymph node-negative disease.
Overall health and functional status: The patient's overall health, performance status, and comorbidities play a significant role in determining treatment options and tolerability. Patients with significant medical issues may be less suitable candidates for intensive treatments like chemoradiation or surgery.
Patient preferences and goals: Patient preferences, values, and treatment goals are essential considerations in developing a treatment plan. Some patients may prioritize preserving organ function and quality of life, while others may prioritize maximizing chances of cure, even if it involves more aggressive treatments.
Response to prior treatments: For recurrent or metastatic anal cancer, prior treatments and response to therapy may influence subsequent treatment decisions. Patients who have previously received radiation therapy may have limited options due to potential radiation-related toxicity and the need to spare surrounding healthy tissues.
Genetic and molecular factors: Molecular profiling of the tumor may provide valuable information about its biological characteristics, including potential targets for therapy and prognostic implications. Certain genetic mutations or biomarkers may influence treatment selection or eligibility for targeted therapies or clinical trials.
Psychosocial and supportive care needs: Consideration of psychosocial factors, including emotional support, caregiver availability, and access to supportive care services, is essential in ensuring comprehensive patient care and optimizing treatment outcomes.
By taking into account these factors and conducting a thorough assessment of each patient's individual circumstances, healthcare providers can develop personalized treatment plans tailored to the specific needs and preferences of patients with anal cancer.
What supportive care measures are typically recommended during and after anal cancer treatment?
Supportive care measures play a crucial role in helping patients manage treatment-related side effects, maintain their quality of life, and optimize overall well-being during and after anal cancer treatment. Some supportive care measures commonly recommended during and after treatment include:
Pain management: Anal cancer treatment may cause pain, discomfort, or nerve-related symptoms. Pain management strategies may include over-the-counter or prescription pain medications, nerve blocks, physical therapy, and complementary therapies such as acupuncture or massage.
Nutritional support: Maintaining adequate nutrition is essential for patients undergoing treatment for anal cancer. Nutritional counseling and support from a registered dietitian can help patients manage treatment-related side effects such as nausea, vomiting, diarrhea, and loss of appetite. Nutritional supplements or dietary modifications may be recommended to ensure patients receive sufficient calories, protein, and essential nutrients.
Hydration: It's important for patients to stay well-hydrated during anal cancer treatment, especially if experiencing symptoms like diarrhea or vomiting. Healthcare providers may recommend increasing fluid intake or using oral rehydration solutions to prevent dehydration.
Management of treatment-related side effects: Chemotherapy, radiation therapy, and surgery for anal cancer can cause various side effects, including fatigue, nausea, vomiting, diarrhea, skin irritation, and sexual dysfunction. Supportive care measures such as anti-nausea medications, topical creams, and supportive garments can help alleviate these side effects and improve patient comfort.
Emotional support: A cancer diagnosis and treatment can be emotionally challenging for patients and their families. Psychosocial support services, such as counseling, support groups, and peer-to-peer support networks, can provide emotional support, coping strategies, and a sense of community for patients navigating the cancer journey.
Management of bowel and bladder function: Anal cancer treatment may affect bowel and bladder function, leading to changes in bowel habits, urinary incontinence, or other pelvic floor issues. Pelvic floor physical therapy, bladder training exercises, and dietary modifications can help manage these symptoms and improve patients' quality of life.
Follow-up care and survivorship planning: After completing treatment for anal cancer, patients require ongoing monitoring and follow-up care to monitor for recurrence, manage late effects of treatment, and address survivorship issues. Survivorship care plans may include regular medical check-ups, cancer surveillance tests, and referrals to specialists for long-term follow-up care.
Health promotion and lifestyle modifications: Encouraging patients to adopt healthy lifestyle habits, such as regular exercise, smoking cessation, and limiting alcohol consumption, can help improve overall health and reduce the risk of cancer recurrence and other chronic health conditions.
Generally, the Anal Cancer Foundation has distilled this advice into the acronym, RESET:
Reset stands for:
- Relief from Pain
- Exercise the Pelvic Floor
- Support from Professionals and Peers
- Eating to Heal
- Therapy for Sexual Health
By providing comprehensive supportive care throughout the cancer journey, healthcare providers can help patients manage treatment-related challenges, improve quality of life, and promote overall well-being during and after treatment for anal cancer.
How does prognosis vary based on the chosen treatment approach for anal cancer?
The prognosis for anal cancer can vary based on several factors, including the chosen treatment approach. Here's how the prognosis may differ depending on the treatment modality:
Surgery: For early-stage anal cancer, surgical resection may offer excellent outcomes with high rates of local control and long-term survival. However, the extent of surgery required (e.g., local excision vs. abdominoperineal resection) and the potential for postoperative complications can influence prognosis. In some cases, surgery alone may be curative, particularly for small tumors without lymph node involvement.
Chemoradiation: Chemoradiation is the standard treatment approach for locally advanced anal cancer and has been shown to achieve high rates of tumor control and long-term survival. When used as definitive treatment, chemoradiation can result in organ preservation and sphincter preservation, preserving patients' quality of life. However, treatment-related toxicities, such as radiation-induced mucositis, dermatitis, and gastrointestinal toxicity, can impact short-term quality of life and may influence long-term outcomes.
Radiation Therapy: Radiation therapy alone may be used in selected cases, particularly for patients who are not candidates for surgery or chemotherapy. While radiation therapy can effectively control localized disease, the risk of treatment-related toxicities and the potential need for salvage surgery or additional treatments may affect prognosis.
Chemotherapy: Systemic chemotherapy is primarily used in combination with radiation therapy (chemoradiation) for locally advanced anal cancer. The addition of chemotherapy to radiation therapy has been shown to improve local control and reduce the risk of distant metastasis, leading to better overall survival outcomes. However, chemotherapy can cause significant side effects, and patients' tolerance to treatment may impact prognosis.
Multimodal Therapy: In cases of recurrent or metastatic anal cancer, multimodal treatment approaches incorporating surgery, chemotherapy, targeted therapy, and/or immunotherapy may be considered. Prognosis in this setting depends on various factors, including the extent of disease, response to treatment, and overall patient health.
Overall, the prognosis for anal cancer is influenced by the stage of the disease, tumor characteristics, treatment response, and patient-specific factors. Multimodal treatment approaches, such as chemoradiation, have significantly improved outcomes for patients with anal cancer, leading to high rates of disease control and long-term survival in many cases. However, close monitoring, ongoing surveillance, and supportive care are essential components of optimizing prognosis and long-term outcomes for patients with anal cancer.
For a glossary of terms, please see our Common Anal Cancer Terms.
Please feel free to Contact Us if you have any further questions or concerns about the treatment for anal cancer.
If you or a loved one have been diagnosed with anal cancer, there are a range of options for treatment as well as new advancements emerging. The different treatment options also depend on the stage of anal cancer the patient is at, which we have broken down below.
Anal cancer treatment can include surgery, chemotherapy, and radiation as well as emerging therapies. There are treatments for squamous and non-squamous forms of anal cancer.
The treatment descriptions here are for general information and are based on general guidelines. However, the information on this site does not reflect medical advice. Talk to your doctor or specialist team about the best treatment options for you.
Treatment options for anal cancer depend on stage and type. In the UK, treatment is usually planned by a specialist multidisciplinary team (MDT), which may include oncologists, a colorectal surgeon and a specialist nurse.
These treatment regimens are primarily for squamous cell carcinoma, which accounts for more than 90% of all anal cancers. These are tumours that are caused by abnormal growth of squamous cells that line most of the anal canal and anal margin (where the anal canal meets the outside skin).
The remaining anal cancers are:
- Basal cell carcinomas of the perianal region: these are considered a subset of squamous cell carcinoma and are extremely rare, comprising less than 1% of all abnormal growths of the anal region.
- Adenocarcinomas (around 5-19% of all anal cancers).
- Malignant melanomas (2-4% of all anal cancers).
Estimates of the prevalence of each of these anal cancers vary based on different studies. Find out more about the different types of anal cancer and the symptoms.
Chemoradiotherapy
The standard treatments for anal cancer are described in NHS information and specialist cancer resources.
For most stage 1 to 3 anal cancers, the standard treatment is chemoradiotherapy, which means chemotherapy and radiotherapy given together. This may sometimes be referred to as the Nigro Protocol, although in the UK the term chemoradiotherapy is more commonly used. Chemoradiotherapy typically includes several weeks of radiotherapy with chemotherapy given during the course of treatment.
Stage IV cancers are usually treated with systemic therapy, most often chemotherapy. In the United States, some people may also be offered chemo-immunotherapy with retifanlimab, but this is not yet routine NHS treatment in England.
Treatment for anal cancer has followed a similar overall approach for many years, with chemoradiotherapy remaining the standard treatment for most localised squamous cell anal cancers. Research is ongoing to improve outcomes and reduce side effects, particularly in advanced disease.
Read more below about the current protocol for surgery, chemotherapy, and radiation. For a helpful list of questions to have with you at your medical appointments, please see our list of Questions to Ask Your Doctor.
Chemotherapy
Chemotherapies are a class of drugs that kill cancer cells and prevent them from multiplying.
Anal cancers between stages 1 and 3 are often treated with radiotherapy together with the chemotherapy drugs mitomycin C and either 5-fluorouracil (5-FU) or capecitabine. For these individuals, chemotherapy is given during the course of radiotherapy. If 5-FU is used, it is usually given into a vein. An oral alternative used in the UK is capecitabine, which is a tablet.
Common side effects of these drugs include, but are not limited to, decreased white blood cells, decreased red blood cells and/or platelets, nausea, vomiting, mouth sores, hair loss, neuropathy, and fatigue. Individuals taking these drugs should talk to their doctors about possible side effects and tell their doctors if they experience these or other side effects.
For stage 4 anal cancer, chemotherapy is usually the main treatment in the UK. Common combinations include carboplatin and paclitaxel, cisplatin and 5-FU, or cisplatin and capecitabine. In the United States, retifanlimab with carboplatin and paclitaxel is FDA-approved for some people with advanced squamous cell carcinoma of the anal canal, but in England NICE is still appraising first-line retifanlimab and it is not yet routine NHS care.
For more information about preparing for chemotherapy, the side effects of chemotherapy, and how to manage them, please see our Chemotherapy page.
Cancer Research UK has put together a useful list of questions that you might want to ask your doctor specifically about chemotherapy for anal cancer.
Looking for someone to talk to about your anal cancer diagnosis? We are here to help.
Radiation
Radiation for anal cancer involves using an external beam of radiation that is directed toward the cancer location to shrink tumours and kill cancer cells. You are likely to have radiotherapy in combination with chemotherapy as your main form of treatment. For people with stage 1 to 3 anal cancer who are having chemoradiotherapy, radiotherapy is typically given every weekday for about 5 and a half weeks. Individuals with stage 4 or recurrent cancer may receive radiotherapy to help control the cancer or relieve symptoms in areas where it has spread.
You may not experience side effects at the beginning of treatment but should expect them as treatment progresses. You may feel the effects for a few weeks after completing treatment, too. This is because radiation has cumulative effects, meaning they build up over time. During radiation, it is important to take care of your skin and drink plenty of fluids.
Side effects of radiation targeted at an anal tumour may include: skin irritation, gastrointestinal and anal discomfort, pain during bowel movements and while urinating, fatigue, diarrhoea, and nausea. Women may experience side effects unique to their anatomy, including vaginal pain, irregular vaginal discharge, and closure of the vagina through the accumulation of scar tissue called stenosis. Side effects unique to the male anatomy may include erectile dysfunction and impotence. Everyone may experience narrowing of the anus, making bowel movements difficult.
Individuals undergoing pelvic radiation for anal cancer may have gastrointestinal and sexual dysfunction that can last throughout their life. Due to the cancer’s location some people may have long-term bowel, pelvic floor or sexual side effects.
Please talk to your radiation oncologist about your specific treatment and side effects, as they vary from person to person. Ask your doctors about mitigating radiation side effects. Management aids may include moisturisers, lubricants, dilators, pelvic rehabilitation, and a referral to a sex therapist who is familiar with pelvic radiation side effects.
For more information about the side effects of radiation and how to manage them, please see our Radiation page.
Sue B.
Stage IIIB
Surgery
Although anal cancer is primarily treated with chemotherapy and radiation protocols, there may be times when surgery is used.
Although uncommon, surgery can be used for some very small stage 1 cancers in the anal margin when the tumour is small and localised, and can be removed without affecting the sphincter muscles. Your specialist team may refer to this type of cancer as “superficially invasive”. During surgery, the area containing the cancer is removed. This operation is called a local excision. If tests after surgery show that there is no evidence of disease, the person will be followed up by their specialist team. If tests after surgery show that anal cancer is still present, the patient will undergo further treatment, which may include another excision or chemoradiotherapy.
Ostomy and Abdominoperineal Resection
Another type of surgery is used for an ostomy. An ostomy is a surgically created opening in the abdominal wall that allows stool to leave the body through an opening on the abdomen (tummy). The opening is called a stoma, and faeces will pass through it into a special collection bag. You will need to learn to care for this area. A specialist stoma nurse will be able to help you with this.
There are different types of ostomies. For anal cancer, the most common ostomy is colostomy.
Some people may need a temporary stoma in selected circumstances during treatment, but this is not routine and depends on their symptoms and individual situation.
There is a much more invasive surgery called an abdominoperineal resection (APR), which may be recommended later in treatment. This is especially the case where chemoradiotherapy has not successfully treated the primary tumour, but cancer has not metastasised to other areas. In an APR, the surgeon removes the anus, rectum, and part of the bowel. This operation results in a permanent colostomy.
Please see our Ostomy Section in Side Effects of Surgery for more information about how to adjust to living with an ostomy, and be sure to speak with your care team about any questions or concerns you may have.
Cancer Research UK has put together a useful list of questions that you might want to ask your doctor about your anal cancer surgery.
Karen, US
Stage IIIB
Treatments by Stage of Anal Cancer
Stages 0
Anal intraepithelial neoplasia (AIN) means there are abnormal cells in the lining of the anus. It is not cancer, but it can sometimes develop into cancer. Some sources may refer to high-grade AIN as stage 0.
AIN may be treated using topical therapies such as imiquimod or 5-FU, and some people may have ablative treatment, a minimally invasive treatment used to remove the top layer of skin, often with a laser. Treatment depends on the grade of the abnormal cells and the specialist service involved.
If you have been diagnosed with AIN, your specialist team will advise you about follow-up and whether treatment or monitoring is needed. Learn more on our anal precancer + screening page.
Stages 1, 2 & 3
The standard treatment for most stage 1 to 3 squamous cell anal cancers is combined chemoradiotherapy, sometimes known as the ‘Nigro Protocol’. See our section above for more details.
Learn more about the side effects of chemotherapy and radiation.
Stage 4
For stage 4 anal cancer, the main treatment is systemic therapy. In the UK this is usually chemotherapy.
Treatment for Recurrent Anal Cancer
Cancer is called ‘recurrent’ when it returns after treatment. It may come back in the same area (local recurrence), in nearby lymph nodes (regional recurrence), or in distant organs such as the lungs, liver or bones.
If your cancer returns, your doctor will carry out tests to understand where it has come back and how far it has spread. This information helps guide treatment decisions, which depend on both the site of recurrence and the treatments you previously received.
For more information please see our section on Recurrent and Advanced Cancer.
Emerging Treatment Options
Immunotherapy
Immunotherapy is a type of treatment that helps the body’s own immune system recognise and attack cancer cells. It works by targeting pathways that cancer cells use to hide from the immune system.
In the United States, a new immunotherapy called retifanlimab-dlwr is approved for some people with advanced anal cancer. It can be used together with chemotherapy for patients who have not received chemotherapy before, or on its own for those who cannot tolerate or whose cancer has progressed after platinum-based treatment. In England, NICE is currently appraising retifanlimab with platinum-based chemotherapy for untreated locally recurrent or metastatic squamous cell anal canal cancer, and it is not yet established as routine treatment.
Different types of immunotherapy are being studied for anal cancer, including cancer vaccines and checkpoint inhibitors. Research in this area is growing, but most immunotherapies remain available only through clinical trials.
Radiosensitizers
Radiosensitizing agents are drugs that increase the sensitivity of tumours to radiation by disrupting their DNA, making radiotherapy more effective. The hope is that lower doses of radiation and chemotherapy will be needed.
Clinical Trials
Clinical trials look at new ways to prevent, detect, or treat disease.
It is worth asking your specialist team about UK trial availability and suitable recruiting centres. They are often the ones who can hopefully connect you to the right enrolment process if you fit the profile.
Genomic Research
Genomic research is also a fast-growing and relatively new area of study in the cancer research world. Cancer genome research compares genes in tumours to genes in healthy, noncancerous tissues in order to understand important differences between the two.
The research goal is to provide insight into what drives cancer development. Ultimately, if we understand how a healthy cell’s DNA has changed to become cancerous, it may indicate areas of the genome that can be targeted by specific drugs. In the future this may mean that each individual has ‘personalised’ medicine where people are no longer treated by the anatomical site but by the genetic mutations in their tumour.
For more information on genomic research, please see our section on Recurrent and Advanced Cancer.
See our Research Roadmap for our vision to advance development of effective treatments for anal and all HPV-related cancers.
Treating Non-Squamous Forms of Anal Cancer
Other forms of anal cancer are adenocarcinoma, basal cell carcinoma, and malignant melanoma. Adenocarcinoma accounts for 5-19% of anal cancer, malignant melanoma for 2-4% and basal cell carcinoma for less than 1% of all abnormal anal growths.
ADENOCARCINOMA
Adenocarcinoma is a rare type of anal cancer that starts in the glandular cells in the anal canal. In the UK, anal adenocarcinoma is usually treated in a similar way to rectal cancer. Treatment may include surgery, chemoradiotherapy and chemotherapy, depending on the stage, exact location and the person’s overall health. Your specialist team can explain how treatment for anal adenocarcinoma compares with treatment for rectal cancer.
For more information about the side effects and how to manage them, please see our Radiation, Chemotherapy and Surgery pages.
BASAL CELL CARCINOMA
Basal cells make up part of the lowest layer of the epidermis, or skin. These cancers usually develop in areas exposed to sunlight and are, in fact, the most common type of cancer in humans.
Anal basal cell carcinomas are rare, however, and treatment is often surgery, planned individually by the specialist team.
MALIGNANT MELANOMA
Melanoma develops from cells known as melanocytes, which produce melanin. This is the pigment responsible for the colour of our skin. Melanocytes are found in our skin and hair, and in other internal organs, including the anus and rectum. Anal melanoma is a rare type of mucosal melanoma, and is mostly found in older adults, aged 60 to 80. In the UK, surgery is usually the main treatment if the cancer has not spread.
As with other types of anal cancer, treatment will depend on the staging and position of the cancer, and your overall health and wellness. Surgery is usually the main option in these cases, as melanomas do not typically respond as well to chemotherapy and radiation as other types of anal cancer.
Early-stage melanomas are usually removed via local excision, while larger tumours or those that have grown into the deeper tissue are removed using abdominoperineal resection.
If the melanoma has spread to other organs, treatment may include surgery, radiotherapy, immunotherapy or targeted treatment, depending on the extent of the disease and specialist advice.
For more information about the side effects and how to manage them, please see our Radiation, Chemotherapy, and Surgery pages.
Anal Cancer and HIV
Immunocompromised people, such as those living with HIV, are at greater risk of high-grade AIN and anal cancer.
Being consistent with HIV treatment and maintaining a high CD4 count can help protect against both of these. Being vigilant with screening for AIN too can help catch problematic cells early before they progress. Additionally, because people with HIV are living longer due to effective treatment, these and other cancers have more time to develop.
The treatment regimen for people living with HIV is usually the same as for those without HIV. It’s important to note that if you are diagnosed with anal cancer but haven’t been tested for HIV, your medical team may discuss testing with you.
Treatment Side Effects
As we’ve discussed throughout, anal cancer treatments can cause side effects that may be quite uncomfortable. Side effects vary from person to person, and each individual thriver may not experience all of the side effects described, and in different intensities.
Learn more on our side effects of treatment page or jump to our Radiation, Chemotherapy and Surgery pages.
Palliative Care
Palliative care is specialized medical care that focuses on providing pain relief. Treatments vary widely and can involve medication, nutrition, mindfulness and relaxation practices, spiritual support, and more. Palliative care specialists work with you to provide that additional support that’s meant to complement your direct cancer care. Make sure to speak with your medical team early in your treatment planning about what palliative care options are available to you. Receiving this type of care alongside traditional, more aggressive cancer therapies often has the impact of improving quality of life and treatment satisfaction.
Support During & After Treatment
Once treatment has finished, people usually have regular hospital follow-up. In the UK, follow-up appointments are usually every 3 to 6 months for 5 years, although the exact schedule varies by hospital, stage and treatment. Generally, if a recurrence happens, it is in the first two years after treatment, which is why follow-up is particularly important during this period. If you are concerned about anything in between follow-up appointments, be sure to see your specialist team as soon as possible.
Due to its rarity and the stigma associated with it, it is extremely important for those with anal cancer to reach out to others in the community for information and support. Anal cancer does not need to be isolating. If you are interested in finding a peer to speak with, the Anal Cancer Foundation has a Peer to Peer Support Program specifically for individuals diagnosed with anal cancer and their caregivers in the USA and United Kingdom.
The Anal Cancer Foundation also has what we call the RESET initiative, launched at our 2022 thriver summit. RESET provides anal cancer thrivers a roadmap to recovery after chemoradiation. Our goal is to arm every thriver (and their caregivers) with the knowledge and resources to move beyond their cancer.
RESET stands for:
- Relief from Pain
- Exercise the Pelvic Floor
- Support from Professionals and Peers
- Eating to Heal
- Therapy for Sexual Health
Peer-to-Peer Support
Anal cancer can often be an isolating experience, and even if you have a supportive circle of family and friends, unless they have been through anal cancer treatment themselves there is often a limit on their understanding. Our peer-to-peer support program aims to address this gap, matching anal cancer thrivers seeking support from trained peer mentors who have been through treatment. Mentors provide 1:1 connection from the framework of those who have shared within this incredibly difficult experience.
We also provide caregiver matching as well.
The cancer thrivers who participate in the program, whether offering or receiving mentorship, build deep friendships and express relief at having found a knowledgeable and empathetic community. After recovery, many support-seekers come back to serve as mentors in the program themselves.
Learn more about our Peer-to-Peer Support Program.
Anal Cancer Treatment FAQs
How does the choice of treatment for anal cancer vary depending on the stage and location of the tumour?
The choice of treatment for anal cancer can vary significantly based on the stage and location of the tumour. Here’s a breakdown of how treatment approaches may differ:
Early-stage (Stage 1) anal cancer:
- For small tumours localised to the anus, surgery may be the primary treatment option. This could involve procedures like local excision or transanal resection to remove the tumour.
- Alternatively, radiation therapy (often combined with chemotherapy) may be used as the primary treatment, particularly for tumours that are not amenable to surgery or for patients who are not suitable candidates for surgery.
Locally advanced (Stage 2 and 3) anal cancer:
- For larger tumours or those that have spread to nearby lymph nodes, a combination of chemotherapy and radiation therapy (chemoradiation) is typically recommended as the primary treatment. This approach helps shrink the tumour and eradicate cancer cells in the surrounding area.
- In some cases, surgery may be performed after chemoradiation to remove any remaining tumour or to address persistent disease.
Metastatic (Stage 4) anal cancer:
- For anal cancer that has spread to distant organs or lymph nodes beyond the pelvis, systemic treatments such as chemotherapy or targeted therapy are typically employed.
- Surgery or radiation therapy may still be used in certain situations to alleviate symptoms or manage complications, but the primary goal of treatment at this stage is usually palliative rather than curative.
Location of the tumour:
- The precise location of the tumour within the anal canal can influence the choice of treatment. Tumours closer to the anal verge may be more amenable to surgical resection, while those located higher in the anal canal may be better treated with radiation therapy or chemoradiation.
- Additionally, tumours that involve the anal margin (the junction between the anus and the skin) may require a different surgical approach or may be more challenging to treat surgically due to cosmetic and functional considerations.
Overall, the stage and location of the tumour play crucial roles in determining the most appropriate treatment strategy for anal cancer, with the goal of achieving optimal outcomes while minimising the risk of recurrence and preserving quality of life.
How do medical experts from different fields play a role in the treatment of anal cancer?
The multidisciplinary approach (this means experts from many different fields of medicine) plays a critical role in the treatment of anal cancer, primarily due to the complexity of the disease and the diverse expertise required to provide comprehensive care. Here’s how different medical specialties collaborate in the management of anal cancer:
Medical Oncology: Medical oncologists specialize in the use of chemotherapy, targeted therapy, and other systemic treatments for cancer. They play a central role in coordinating chemotherapy regimens, both as part of definitive treatment (such as concurrent chemoradiation for locally advanced disease) and in the management of metastatic anal cancer.
Radiation Oncology: Radiation oncologists are responsible for planning and delivering radiation therapy to treat anal cancer. They work closely with medical oncologists to determine the optimal radiation dose and technique, taking into account factors such as tumour size, location, and stage. Radiation therapy is often a key component of treatment for anal cancer, either alone or in combination with chemotherapy.
Surgical Oncology: Surgical oncologists specialize in the surgical management of cancer. While surgery is not always the primary treatment for anal cancer, it may be necessary in certain cases, such as early-stage tumours or persistent disease after chemoradiation. Surgical oncologists may perform procedures such as local excision, abdominoperineal resection (APR), or inguinal lymph node dissection as part of the treatment plan.
Gastroenterology/Colorectal Surgery: Gastroenterologists and colorectal surgeons are involved in the diagnosis and management of anal cancer, particularly in evaluating patients with anal lesions and performing procedures such as biopsies and endoscopic evaluations. They may also be involved in the surgical management of anal cancer, particularly for tumours located in the anal canal or involving the anal margin.
Pathology: Pathologists analyze tissue samples (biopsies) obtained from anal lesions to establish a definitive diagnosis of anal cancer and provide important information about the tumour’s characteristics, such as its histological type, grade, and molecular features. This information helps guide treatment decisions and prognostication.
Radiology: Radiologists play a crucial role in diagnosing anal cancer and assessing its extent through imaging studies such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET). Radiologists collaborate with other members of the multidisciplinary team to stage the disease accurately and monitor treatment response.
Supportive Care Providers: In addition to the core treatment specialties, supportive care providers such as nurses, oncology pharmacists, nutritionists, and social workers are essential members of the multidisciplinary team. They provide supportive care services, manage treatment-related side effects, address patients’ psychosocial needs, and optimise quality of life throughout the treatment journey.
By bringing together specialists from various disciplines, the multidisciplinary approach ensures that patients with anal cancer receive individualised, evidence-based care that integrates the latest advances in treatment and supportive care. This collaborative model helps optimise treatment outcomes, minimise treatment-related complications, and improve overall patient satisfaction and well-being.
Are there specific factors or patient characteristics that can influence treatment options for anal cancer?
Yes, several factors and patient characteristics can influence treatment options for anal cancer. These include:
Stage of cancer: The stage of anal cancer, which indicates the extent of disease, is a crucial factor in determining the appropriate treatment approach. Treatment options may vary for early-stage (1 and 2) versus locally advanced (3) or metastatic (4) disease.
Tumour size and location: The size and location of the tumour within the anal canal or surrounding tissues can impact treatment decisions. Tumours closer to the anal verge may be more amenable to surgical resection, while those located higher in the anal canal may be better treated with radiation therapy or chemoradiation.
Lymph node involvement: The presence or absence of lymph node involvement (regional lymph node metastasis) affects treatment planning and prognosis. Lymph node-positive disease may require more aggressive treatment, such as chemoradiation or lymph node dissection, compared to lymph node-negative disease.
Overall health and functional status: The patient’s overall health, performance status, and comorbidities play a significant role in determining treatment options and tolerability. Patients with significant medical issues may be less suitable candidates for intensive treatments like chemoradiation or surgery.
Patient preferences and goals: Patient preferences, values, and treatment goals are essential considerations in developing a treatment plan. Some patients may prioritise preserving organ function and quality of life, while others may prioritise maximising chances of cure, even if it involves more aggressive treatments.
Response to prior treatments: For recurrent or metastatic anal cancer, prior treatments and response to therapy may influence subsequent treatment decisions. Patients who have previously received radiation therapy may have limited options due to potential radiation-related toxicity and the need to spare surrounding healthy tissues.
Genetic and molecular factors: Molecular profiling of the tumour may provide valuable information about its biological characteristics, including potential targets for therapy and prognostic implications. Certain genetic mutations or biomarkers may influence treatment selection or eligibility for targeted therapies or clinical trials.
Psychosocial and supportive care needs: Consideration of psychosocial factors, including emotional support, caregiver availability, and access to supportive care services, is essential in ensuring comprehensive patient care and optimising treatment outcomes.
By taking into account these factors and conducting a thorough assessment of each patient’s individual circumstances, healthcare providers can develop personalised treatment plans tailored to the specific needs and preferences of patients with anal cancer.
What supportive care measures are typically recommended during and after anal cancer treatment?
Supportive care measures play a crucial role in helping patients manage treatment-related side effects, maintain their quality of life, and optimise overall well-being during and after anal cancer treatment. Some supportive care measures commonly recommended during and after treatment include:
Pain management: Anal cancer treatment may cause pain, discomfort, or nerve-related symptoms. Pain management strategies may include over-the-counter or prescription pain medications, nerve blocks, physical therapy, and complementary therapies such as acupuncture or massage.
Nutritional support: Maintaining adequate nutrition is essential for patients undergoing treatment for anal cancer. Nutritional counselling and support from a registered dietitian can help patients manage treatment-related side effects such as nausea, vomiting, diarrhoea, and loss of appetite. Nutritional supplements or dietary modifications may be recommended to ensure patients receive sufficient calories, protein, and essential nutrients.
Hydration: It’s important for patients to stay well-hydrated during anal cancer treatment, especially if experiencing symptoms like diarrhoea or vomiting. Healthcare providers may recommend increasing fluid intake or using oral rehydration solutions to prevent dehydration.
Management of treatment-related side effects: Chemotherapy, radiation therapy, and surgery for anal cancer can cause various side effects, including fatigue, nausea, vomiting, diarrhoea, skin irritation, and sexual dysfunction. Supportive care measures such as anti-nausea medications, topical creams, and supportive garments can help alleviate these side effects and improve patient comfort.
Emotional support: A cancer diagnosis and treatment can be emotionally challenging for patients and their families. Psychosocial support services, such as counselling, support groups, and peer-to-peer support networks, can provide emotional support, coping strategies, and a sense of community for patients navigating the cancer journey.
Management of bowel and bladder function: Anal cancer treatment may affect bowel and bladder function, leading to changes in bowel habits, urinary incontinence, or other pelvic floor issues. Pelvic floor physical therapy, bladder training exercises, and dietary modifications can help manage these symptoms and improve patients’ quality of life.
Follow-up care and survivorship planning: After completing treatment for anal cancer, patients require ongoing monitoring and follow-up care to monitor for recurrence, manage late effects of treatment, and address survivorship issues. Survivorship care plans may include regular medical check-ups, cancer surveillance tests, and referrals to specialists for long-term follow-up care.
Health promotion and lifestyle modifications: Encouraging patients to adopt healthy lifestyle habits, such as regular exercise, smoking cessation, and limiting alcohol consumption, can help improve overall health and reduce the risk of cancer recurrence and other chronic health conditions.
Generally, the Anal Cancer Foundation has distilled this advice into the acronym, RESET:
RESET stands for:
- Relief from Pain
- Exercise the Pelvic Floor
- Support from Professionals and Peers
- Eating to Heal
- Therapy for Sexual Health
By providing comprehensive supportive care throughout the cancer journey, healthcare providers can help patients manage treatment-related challenges, improve quality of life, and promote overall well-being during and after treatment for anal cancer.
How does prognosis vary based on the chosen treatment approach for anal cancer?
The prognosis for anal cancer can vary based on several factors, including the chosen treatment approach. Here’s how the prognosis may differ depending on the treatment modality:
Surgery: For early-stage anal cancer, surgical resection may offer excellent outcomes with high rates of local control and long-term survival. However, the extent of surgery required (e.g., local excision vs. abdominoperineal resection) and the potential for postoperative complications can influence prognosis. In some cases, surgery alone may be curative, particularly for small tumours without lymph node involvement.
Chemoradiation: Chemoradiation is the standard treatment approach for locally advanced anal cancer and has been shown to achieve high rates of tumour control and long-term survival. When used as definitive treatment, chemoradiation can result in organ preservation and sphincter preservation, preserving patients’ quality of life. However, treatment-related toxicities, such as radiation-induced mucositis, dermatitis, and gastrointestinal toxicity, can impact short-term quality of life and may influence long-term outcomes.
Radiation Therapy: Radiation therapy alone may be used in selected cases, particularly for patients who are not candidates for surgery or chemotherapy. While radiation therapy can effectively control localised disease, the risk of treatment-related toxicities and the potential need for salvage surgery or additional treatments may affect prognosis.
Chemotherapy: Systemic chemotherapy is primarily used in combination with radiation therapy (chemoradiation) for locally advanced anal cancer. The addition of chemotherapy to radiation therapy has been shown to improve local control and reduce the risk of distant metastasis, leading to better overall survival outcomes. However, chemotherapy can cause significant side effects, and patients’ tolerance to treatment may impact prognosis.
Multimodal Therapy: In cases of recurrent or metastatic anal cancer, multimodal treatment approaches incorporating surgery, chemotherapy, targeted therapy, and/or immunotherapy may be considered. Prognosis in this setting depends on various factors, including the extent of disease, response to treatment, and overall patient health.
Overall, the prognosis for anal cancer is influenced by the stage of the disease, tumour characteristics, treatment response, and patient-specific factors. Multimodal treatment approaches, such as chemoradiation, have significantly improved outcomes for patients with anal cancer, leading to high rates of disease control and long-term survival in many cases. However, close monitoring, ongoing surveillance, and supportive care are essential components of optimising prognosis and long-term outcomes for patients with anal cancer.
For a glossary of terms, please see our Common Anal Cancer Terms.
Please feel free to Contact Us if you have any further questions or concerns about the treatment for anal cancer.
Share this: on Twitter on Facebook
